Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01626599 · ClinicalTrials.gov registry record · NA
Study to Evaluate a New Device Designed to Collect Heart Activity and Body Movement Data
A NA study, sponsored by Cyberonics.
- Completed
- Registry status
- NA
- Development phase
- 147
- Enrollment target
NCT01626599: Completed NA study, sponsored by Cyberonics.
NCT01626599 is a NA study that has completed, run by Cyberonics. The registered enrollment target is 147 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01626599, a NA study, has completed, sponsored by Cyberonics.
- COMPLETED
- Registry status
- NA
- Development phase
- 147 participants
- Enrollment target
Study Summary
This study is designed to collect data to support development of a novel product designed to sense changes in heart rate or movement during periods of sleep in people with epilepsy. When a potential seizure is detected, the system sends out an audio-visual notification.
Primary Outcome
This study is designed to collect usability data from the intended use population of people with epilepsy and their caregivers to support development of a novel product designed to capture ECG signals and accelerometer data.
Interventions
- DEVICE ProGuardian
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 147 participants |
| Start Date | 2012-06 |
| Est. Completion | 2014-04 |
| Phase | NA |
What the finished NCT01626599 record still lists
NCT01626599 is an interventional study that assigns participants to a tested intervention. The registered 147 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which ProGuardian is the first listed.
NCT01626599 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01626599 about?
NCT01626599 is a clinical study titled "Study to Evaluate a New Device Designed to Collect Heart Activity and Body Movement Data". This study is designed to collect data to support development of a novel product designed to sense changes in heart rate or movement during periods of sleep in people with epilepsy. When a potential seizure is detected, the system sends out an audio-visual notification.
What is the current status of trial NCT01626599?
This trial is currently completed. It is a NA study. The enrollment target is 147 participants. The study started on 2012-06. Estimated completion is 2014-04.
What interventions are being tested in trial NCT01626599?
The interventions under investigation include: ProGuardian (DEVICE).
Who is sponsoring clinical trial NCT01626599?
This trial is sponsored by Cyberonics, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01626599's enrollment target sits among peer trials
147 703rd of 2000 higher than 1,297 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04396613 · 147 participants · NA
Wound Closure Techniques in Primary Spine Surgery
- NCT04851119 · 147 participants · Phase 1
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- NCT05523947 · 147 participants · Phase 1
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
- NCT06121843 · 147 participants · Phase 1
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia